Abstract
The present case involves a 47-yr-old woman with Cushing’s disease due to pituitary macroadenoma. The patient had suffered from hypertension and obesity for two yr. Her serum cortisol levels were moderately elevated throughout the observation period, and dexamethasone failed to suppress the cortisol secretion. Plasma ACTH levels were markedly high (>100 pg/ml) and did not respond to CRH provocation. Gel filtration analysis of the patient’s plasma detected the existence of big ACTH molecules, which eluted with a peak of authentic 1–39 ACTH. Cranial magnetic resonance imaging (MRI) revealed a 3 cm pituitary tumor occupying the sellar region and right cavernous sinus with diffuse enhancement by gadolinium. The pituitary mass was removed by transsphenoidal surgery, and was pathologically identified as compatible to ACTH-producing pituitary adenoma by immunohistochemistry. RT-PCR analysis of total cellular RNA extracted from the resected adenoma revealed a relatively high expression level of dopamine D2 receptor (D2R) mRNA. Therefore, a long-acting D2R agonist, cabergoline (0.25 to 0.5 mg/week), was administered for the remnant adenoma, which gradually reduced ACTH levels in 90 days. In addition, cranial MRI exhibited shrinkage of the remnant pituitary mass after a 6-month treatment with cabergoline. This case demonstrates the efficacy of cabergoline to treat Cushing’s disease caused by pituitary macroadenoma secreting aberrant ACTH molecules.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 1992, 13: 220–40.
Selvais P, Donckier J, Buysschaert M, Maiter D. Cushing’s disease: a comparison of pituitary corticotroph micro — adenomas and macroadenomas. Eur J Endocrinol 1998, 138: 153–9.
Katznelson L, Bogan JS, Trob JR, et al. Biochemical assessment of Cushing’s disease in patients with corticotroph macroadenomas. J Clin Endocrinol Metab 1998, 83: 1619–23.
Mampalam TJ, Tyrrell JB, Wilson CB. Transsphenoidal microsurgery for Cushing disease. A report of 216 cases. Ann Intern Med 1988, 109: 487–93.
Shimon I, Melmed S. Management of pituitary tumors. Ann Intern Med 1998, 129: 472–83.
Hashimoto K, Kaneda T, Nagano I, Asaba K, Takeda K, Takao T. Pituitary adenoma showing intermittent secretion of high molecular weight adrenocorticotropin without evidenice of Cushing’s disease. Horm Res 1999, 52: 39–44.
Takeda M, Otsuka F, Suzuki J, et al. Involvement of activin/BMP system in development of human pituitary gonadotropinomas and nonfunctioning adenomas. Biochem Biophys Res Commun 2003, 306: 812–8.
Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 1994, 331: 904–9.
Verhelst J, Abs R, Maiter D, et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 1999, 84: 2518–22.
Abs R, Verhelst J, Maiter D, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 1998, 83: 374–8.
T’Sjoen G, Defeyter I, Van De Saffele J, Rubens R, Vandeweghe M. Macroprolactinoma associated with Cushing’s disease, successfully treated with cabergoline. J Endocrinol Invest 2002, 25: 172–5.
Pivonello R, Faggiano A, Di Salle F, Filippella M, Lombardi G, Colao A. Complete remission of Nelson’s syndrome after 1-year treatment with cabergoline. J Endocrinol Invest 1999, 22: 860–5.
Petrossians P, Ronci N, Valdes Socin H, et al. ACTH silent adenoma shrinking under cabergoline. Eur J Endocrinol 2001, 144: 51–7.
Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 2001, 22: 724–63.
Renner U, Arzberger T, Pagotto U, et al. Heterogeneous dopamine D2 receptor subtype messenger ribonucleic acid expression in clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 1998, 83: 1368–75.
Murata Y, Ando H, Nagasaka T, et al. Successful pregnancy after bromocriptine therapy in an anovulatory woman complicated with ovarian hyperstimulation caused by follicle-stimulating hormone-producing plurihormonal pituitary microadenoma. J Clin Endocrinol Metab 2003, 88: 1988–93.
Saiardi A, Borrelli E. Absence of dopaminergic control on melanotrophs leads to Cushing’s-like syndrome in mice. Mol Endocrinol 1998, 12: 1133–9.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Miyoshi, T., Otsuka, F., Takeda, M. et al. Effect of cabergoline treatment on Cushing’s disease caused by aberrant adrenocorticotropin-secreting macroadenoma. J Endocrinol Invest 27, 1055–1059 (2004). https://doi.org/10.1007/BF03345309
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03345309